연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
2217. Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age.
Seo YS, Kim HJ, Wu HG, Choi SM, Park S
Thorac Cancer. 2019 Jun;10(6):1489-1499
Link
2216. Identification of FES as a Novel Radiosensitizing Target in Human Cancers.
Kim BH, Kim YJ, Kim MH, Na YR, Jung D, Seok SH, Kim J, Kim HJ.
Clin Cancer Res. 2019 Oct 1
Link
2215. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL1,2, Kim HP1,2, Cho YW1,2, Min DW1,2, Cheon SK1,2, Lim YJ3, Song SH2, Kim SJ4, Han SW2,3, Park KJ5, Kim TY1,2,3.
Int J Cancer. 2019 Jan 15;144(2):389-401. doi: 10.1002/ijc.31662. Epub 2018 Nov 29.
Link
2214. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Lee Y1, Kim TM2, Kim DW3, Kim S4, Kim M3, Keam B3, Ku JL1, Heo DS3.
J Thorac Oncol. 2019 Sep;14(9):1556-1566. doi: 10.1016/j.jtho.2019.05.006. Epub 2019 May 17.
Link
2213. NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
Park HR1, Ahn YO2, Kim TM3, Kim S4, Kim S1, Lee YS1, Kim M5, Keam B5, Kim DW5, Heo DS5.
Cytotherapy. 2019 Jun;21(6):603-611. doi: 10.1016/j.jcyt.2019.03.312. Epub 2019 Apr 20.
Link
2212. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.
Kim WJ1, Dho YS1, Ock CY2, Kim JW1, Choi SH3, Lee ST4, Kim IH5, Kim TM6, Park CK7.
J Neurooncol. 2019 Jun;143(2):321-328. doi: 10.1007/s11060-019-03167-2. Epub 2019 Apr 13.
Link
2211. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M1, Kim S2,3, Lee JK4, Yoon SO5, Park HS6, Hong SW6, Park WS7, Kim JE8, Kim J4, Keam B9,2, Kim HJ10, Kang HJ11,2, Kim DW9,2, Jung KC1, Kim YT2,12, Heo DS9,2, Kim TM13,2, Jeon YK14,2.
Oncologist. 2019 Aug;24(8):e740-e748. doi: 10.1634/theoncologist.2018-0477. Epub 2019 Jan 29.
Link
2210. Disulfiram, a re-positioned aldehyde dehydrogenase inhibitor, enhances radiosensitivity of human glioblastoma cells in vitro.
Koh HK, Seo SY, Kim JH, Kim HJ, Chie EK, Kim SK, Kim IH.
Cancer Res Treat. 2019;51(2):696-705
Link
2209. Radiosensitization of glioblastoma cells by a novel DNA methyltransferase inhibiting phthalimido-alkanamide derivative.
Wee CW, Kim JH, Kim HJ, Kang H-C, Suh SY, Shin BS, Ma E, Kim IH
Anticancer Res 2019 Feb;39(2):759-769.
Link
2208. A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage
Kang H-C, Chie EK, Kim HJ, Kim JH, Kim IH, Kim K Shin BS, Ma E
Invest New Drugs. 2019; Dec;37(6):1158-1165.
Link